Cargando…
Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
In the recent years, using genetically modified T cells has been known as a rapid developing therapeutic approach due to the heartwarming results of clinical trials with patients suffering from relapsed or refractory (R/R) hematologic malignancies such as R/R Acute Lymphoblastic Leukemia (R/R ALL)....
Autores principales: | Hashem Boroojerdi, Mohadese, Rahbarizadeh, Fatemeh, Safarzadeh Kozani, Pouya, Kamali, Elahe, Safarzadeh Kozani, Pooria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549730/ https://www.ncbi.nlm.nih.gov/pubmed/33047234 http://dx.doi.org/10.1007/s12032-020-01416-3 |
Ejemplares similares
-
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021) -
Novel antigens of CAR T cell therapy: New roads; old destination
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021) -
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021) -
Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021) -
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)